Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
Status:
Not yet recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce
progression to and severity of sepsis in older patients. The central hypothesis is that a
threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs,
contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes
timely treatment with fisetin will interrupt this pathway.
A multicenter, randomized, adaptive allocation clinical trial to identify the most
efficacious dose of the senolytic fisetin to reduce the composite cardiovascular,
respiratory, and renal sequential organ failure assessment score at 1 week, and predict the
probability of success of a definitive phase III clinical trial.